ionis agt-lrx
Nucleic acidexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 6, 2017 (NCT03101878)
Timeline
Indications
Mechanism of action
- Angiotensin II type 2 (AT-2) receptorANTISENSE INHIBITOR
AGTR2 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ionis agt-lrx
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04836182 | Phase 2 | Jun 8, 2021 | Ionis Pharmaceuticals, Inc. |
| NCT04714320 | Phase 2 | Mar 4, 2021 | Ionis Pharmaceuticals, Inc. |
| NCT04083222 | Phase 2 | Nov 30, 2019 | Ionis Pharmaceuticals, Inc. |
| NCT03714776 | Phase 2 | Jan 3, 2019 | Ionis Pharmaceuticals, Inc. |
| NCT03101878 | Phase 1/Phase 2 (Phase 2) | Apr 6, 2017 | Ionis Pharmaceuticals, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | For profit | 5 | 5 | 1 | 2017 |
1 organizations
Page 1 / 1